Jeffrey Scott Riley

CIK: 0001487645

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

GANX

Gain Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (2 total)

GANX
Gain Therapeutics, Inc.
Jul 15, 2026
Award(A)
Stock Option (right to buy)
Direct
25K shares-
GANX
Gain Therapeutics, Inc.
Jun 24, 2025
Award(A)
Stock Option (right to buy)
Direct
15K shares-

		Type	Shares	Price		Ownership
Jul 15, 2026	GANX Gain Therapeutics, Inc.	Award(A) Stock Option (right to buy)	25,000	-	-	Direct
Jun 24, 2025	GANX Gain Therapeutics, Inc.	Award(A) Stock Option (right to buy)	15,000	-	-	Direct

1-2 of 2 transactions

About Riley Jeffrey Scott

Riley Jeffrey Scott (SEC CIK 0001487645) files insider reports with the SEC as Director of Gain Therapeutics, Inc. (GANX).

Signal8 holds 2 ownership filings by Riley Jeffrey Scott, all Form 4s, filed between Jun 25, 2025 and Jul 17, 2026. Those filings report 2 transactions, from Jun 24, 2025 to Jul 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Riley Jeffrey Scott's filings is in BETHESDA, MD.

Recent filings by Riley Jeffrey Scott

Jul 15, 2026: Grant or award of GANX derivative securities (Form 4, code A).
Jun 24, 2025: Grant or award of GANX derivative securities (Form 4, code A).

Other insiders filing for Gain Therapeutics, Inc. (GANX)

How to read Form 4 transaction codes